SUMMARY In a six year period up to the end of December 1985 fine needle aspiration cytology specimens of the breast were obtained from 562 apparently healthy women invited to participate in a breast cancer screening programme. Of these, 397 had a biopsy and 173 cancers were confirmed histologically. For the diagnosis of cancer, the procedure was less successful than in symptomatic cases. The main factors influencing success were the aspirator, the small size of many cancers, and the occult nature of the lesions seen only on mammography. Retrospective analysis of the figures shows that combining the results of FNA cytology in a triple assessment with physical and mammographical findings for restricted selection means that the number of benign biopsy specimens could be reduced considerably.
Cytology is a well established method of investigating breast lesions in symptomatic patients, but there is little recorded information about its use as part of a well woman screening programme. This paper reports the results of fine needle aspiration (FNA) cytology in invited well women attending a breast screening clinic over a period of six years up to the end of December 1985 . In this paper we assess the accuracy of fine needle aspiration cytology in preoperative diagnosis of cancer and its contribution to the selection of cases for biopsy in a screening programme.
Material and methods

SOURCE OF CLINICAL MATERIAL U
The FNA cytology specimens were taken from invited well women participating in the Edinburgh Breast Screening Project (EBSP)1 which forms part of the United Kingdom seven year trial of early breast cancer detection.2 The decision to recommend for biopsy, based on clinical and mammographical examination, was taken at a surgical review clinic. As part of the protocol and before any further investigation took place, a clinic assessment category, reflecting the expected biopsy result, was recorded for each invited well woman; this category was for internal clinic guidance. The aspirates were obtained from solid lesions and the cytology assessed as previously described.3
Accepted for publication 5 These assessments show clearly that size and physical detectability, in addition to the aspirator, have a major influence on the diagnostic success of FNA cytology in the detection of cancer by screening.
SELECTION OF CASES FOR BIOPSY
Of the 397 cases put forward for biopsy, 224 had benign pathology reports (table 1) , and in the context of screening were therefore false positive selections. A clinic assessment category based on combined clinical and mammographical findings was recorded independently at the special review clinic when the decision to biopsy was made. Table 3 shows the distribution of biopsy cases over the five categories; table 4 shows the correlation of the clinic assessment with the cytology reports. The two modalities did not always identify the same cases as being suspicious or malignant. Cytology indicated fewer (141) cases as positive or suspicious than the clinic assessment (265). There was a group of 13 cases where the cytology assessment of positive or suspicious was at variance with the benign clinic assessment. Nine of these 13 cases were histologically confirmed as cancers. A total of 12 cases assigned to clinic category 5 were found to be histologically benign.
Standard measures of performance of a selection procedure-namely, sensitivity, specificity, and pre- restricted selection, when combined with clinic assessment category; the yield of cancer is then maximised while maintaining a greater than 50% reduction in benign biopsy specimens. It is acknowledged that referral for biopsy in screening may be influenced by several other factors not detailed here. The surgical policy adopted for symptomatic women to biopsy all palpable discrete lumps may be followed. There is also an awareness that many of the changes detected at screening are subtle and may not be perceived by a second examiner at a separate procedure for aspiration. Indeed, truly occult lesions, such as the one missed in the restricted triple assessment, require needle localisation biopsy" unless a stereotactic device is available for the cytology to achieve adequate levels of sensitivity.12
The performance measures obtained in this analysis refer to a non-consecutive series representing 57% of biopsies generated by screening and may not truly reflect the results from the full spectrum of such a programme. They also do not represent the sensitivity, specificity, and predictive value of the overall screening procedure; they do, however, provide information that is relevant to the optimal use and interpretation of results. In particular, appreciation of the factors influencing success will assist decisions on whether to repeat the procedure or to defer the decision to biopsy. The role of the cytologist is assumed to be a constant factor in the present series, where examination was virtually restricted to two individuals who frequently conferred, in particular with cases at the borderline of positive and suspicious designation. The proportion of reported cases allotted to the suspicious category varies from 31 %7 to 24.4%8 and signifies the variation in reporting policies of cytologists. It is worth noting that the 20% termed suspicious for the screening series was double that found in our larger series of symptomatic cases. 6 The most likely explanations for this include poor representation of malignant cells in the specimen as a consequence of size and occult nature, as well as the tendency of screening
